Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 310

The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.

Meta-analysis of the Age-Dependent Efficacy of Multiple Sclerosis Treatments

Open access
Weideman, Ann Marie, Tapia-Maltos, Marco Aurelio, Johnson, Kory, Greenwood, Mark, Bielekova, Bibiana·2017·Frontiers in Neurology

Abstract

Objective: To perform a meta-analysis of randomized, blinded, multiple sclerosis (MS) clinical trials to test the hypothesis that efficacy of immunomodulatory disease-modifying therapies (DMTs) on MS disability progression is strongly dependent on age. Methods: We performed a literature search with pre-defined criteria and extracted relevant features from 38 clinical trials that assessed efficacy of DMTs on disability progression. We fit a linear regression, weighted for trial sample size and duration, to examine the hypothesis that age has a defining effect on the therapeutic efficacy of immunomodulatory DMTs. Results: More than 28,000 MS subjects participating in trials of 13 categories of immunomodulatory drugs are included in the meta-analysis. The efficacy of immunomodulatory DMTs on MS disability strongly decreased with advancing age (R2 = 0.6757, p = 6.39e-09). Inclusion of baseline EDSS did not significantly improve the model. The regression predicts zero efficacy beyond approximately age 53 years. The comparative efficacy rank derived from the regression residuals differentiates high and low efficacy drugs. High efficacy drugs outperform low efficacy drugs in inhibiting MS disability only for patients younger than 40.5 years. Conclusions: The meta-analysis supports the notion that progressive MS is simply a later stage of the MS disease process and that age is an essential modifier of a drug efficacy. Higher efficacy treatments exert their benefit over lower efficacy treatments only during early stages of MS, and, after age 53, the model suggests that there is no predicted benefit to receiving immunomodulatory DMTs for the average MS patient.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fneur.2017.00577

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 39 references

Cited by

See all 310

Metadata

Authors
Weideman, A. M., Tapia-Maltos, M. A., Johnson, K., Greenwood, M., & Bielekova, B.
Venue
Frontiers in Neurology
Published
2017-11-10
Volume
8
Pages
577-577
ISSN
1664-2295 (ISSN-L)
OpenAlex
W2767362256
Cited by
310
References
39
FWCI
3.52
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Meta-analysis of the Age-Dependent Efficacy of Multiple Sclerosis Treatments. https://app.cochat.ai/papers/10.3389/fneur.2017.00577
The paper
Weideman, A. M., Tapia-Maltos, M. A., Johnson, K., Greenwood, M., & Bielekova, B. (2017). Meta-analysis of the Age-Dependent Efficacy of Multiple Sclerosis Treatments. Frontiers in Neurology. https://doi.org/10.3389/fneur.2017.00577

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.